Top 3 Health Care Stocks That May Rocket Higher In December
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Fiscal Year: January - December
Perrigo Company plc (PRGO), listed on the NYSE, has a market capitalization of $. As of Dec 07, 2025, the stock is trading at $13.44 per share, offering investors a clear view of its current market value. Perrigo Company plc is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of N/A , investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Perrigo Company plc also offers a dividend yield of 8.63%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Perrigo Company plc (PRGO) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Perrigo Company plc is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Perrigo Company plc, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Perrigo Company plc is 7.21, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Perrigo Company plc (PRGO) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Perrigo Company plc (PRGO) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Perrigo Company plc (PRGO) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Perrigo Company plc. To access the full SS Score, consider upgrading your subscription.
Perrigo Company plc is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of N/A . Investors should compare these metrics with industry peers to gauge whether Perrigo Company plc is outperforming or underperforming within its sector.
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
DUBLIN , Nov. 18, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer health products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo ...
Perrigo Company plc ( PRGO) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Bradley Joseph - Vice President of Global Investor Relations & Corporate Communications Patrick Loc...
Perrigo said on Wednesday it has initiated a strategic review of its infant formula business as the consumer health company shifts its focus to higher-margin branded products.
Amid Soft Market Consumption Trends, Achieved Q3 2025 Dollar, Unit and Volume Share(1) Gains in 5 of 7 Over-The-Counter ("OTC") Store Brand Categories and Dollar Share Gains in Key Brands Despite Mark...
DUBLIN , Nov. 5, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or "the Company"), a leading provider of consumer health products, today announced that it is initiating a strategic r...
DUBLIN , Nov. 4, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer health products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo B...
A federal judge on Friday said 36 drugmakers and executives must face nearly all claims in an antitrust lawsuit brought by most U.S. states, accusing them of conspiring to fix prices of 80 generic dru...
DUBLIN , Oct. 29, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of consumer health products, today announced that its Board of Directors declared a quarterly dividen...
“Hi-Yield S&P Aristocrats... in the S&PComposite1500Index… combine two key-traits: (1) a long track-record of consistently-raising-dividends (typically at-least 20–25 consecutive-years, but not-always...
DUBLIN , Oct. 22, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its third quarter 2025 financial resu...
Perrigo offers an attractive valuation as operational improvements, debt reduction, and new products like Opill show early signs of turnaround. PRGO's efficiency initiatives and divestments have impro...
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Brands Will Donate One Pack of Opill® to NY Birth Control Access Project for Each Opill®-Themed Chill Tips Set Sold GRAND RAPIDS, Mich. , Oct. 9, 2025 /PRNewswire/ -- Today, Perrigo Company plc (NYSE:...
The article highlights the top ten S&P Hi-Yield Aristocrats for September, with nine stocks offering attractive yields and fair pricing for dividend investors. Analyst forecasts project potential net ...
DUBLIN , Aug. 20, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduar...
Perrigo Company plc (NYSE:PRGO) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Bradley Joseph - Vice President of Global Investor Relations & Corporate Communications...
Company Advanced its 'Three-S' Plan (Stabilize, Streamline, and Strengthen) with Recently Announced Agreement to Sell Dermacosmetics Business, Scaling of Global Operating Growth Model, and Upgraded Br...
DUBLIN , July 29, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduar...
DUBLIN , July 23, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its second quarter 2025 financial res...
Transaction Advances Company's 'Three-S' Plan to Streamline its Portfolio and Strengthen Focus on its 'High-Grow' Brands Total Consideration of Up to €327 Million, Consisting of €300 Million in Upfron...
Company to Scale and Optimize Global Category-Led, Market Activation Growth Model Roberto Khoury, EVP & President Consumer Self-Care International (CSCI), Appointed to New Position of EVP & Chief Comm...
Beginning July 1, 2025, a month-long giveaway contest will award 100 winners with two months' worth of Good Start® | Dr. Brown's™ Gentle Pro™ baby formula plus Dr. Brown's products (valued at $516.49)...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2025 | 329.82M | 42.59% | Est @42.6% |
| 2026 | 428.33M | 29.87% | Analyst x3 |
| 2027 | 438.67M | 2.41% | Analyst x3 |
| 2028 | 436.00M | -0.61% | Analyst x2 |
| 2029 | 470.50M | 7.91% | Analyst x2 |
| 2030 | 480.84M | 2.20% | Est @2.2% |
| 2031 | 491.77M | 2.27% | Est @2.3% |
| 2032 | 503.20M | 2.33% | Est @2.3% |
| 2033 | 515.09M | 2.36% | Est @2.4% |
| 2034 | 526.55M | 2.23% | Est @2.2% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2023A | 303.80M | 1.00 | 303.80M |
| 2024A | 231.30M | 1.00 | 231.30M |
| 2025E | 329.82M | 1.07 | 309.11M |
| 2026E | 428.33M | 1.14 | 376.24M |
| 2027E | 438.67M | 1.21 | 361.13M |
| 2028E | 436.00M | 1.30 | 336.40M |
| 2029E | 470.50M | 1.38 | 340.23M |
| 2030E | 480.84M | 1.48 | 325.88M |
| 2031E | 491.77M | 1.57 | 312.36M |
| 2032E | 503.20M | 1.68 | 299.56M |
| 2033E | 515.09M | 1.79 | 287.39M |
| 2034E | 526.55M | 1.91 | 275.34M |
| Terminal | 12.86B | 1.91 | 6.72B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.